Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.02)
# 4,499
Out of 5,172 analysts
5
Total ratings
20%
Success rate
-40.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNTI Senti Biosciences | Initiates: Outperform | $6 | $0.92 | +552.17% | 1 | Nov 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $14.06 | +547.23% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $1.47 | +716.33% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $114.18 | -1.91% | 1 | Oct 28, 2022 |
Senti Biosciences
Nov 21, 2025
Initiates: Outperform
Price Target: $6
Current: $0.92
Upside: +552.17%
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $14.06
Upside: +547.23%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.47
Upside: +716.33%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $114.18
Upside: -1.91%